Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg/kg injectable dose of marbofloxacin compared with one or two doses of 7.5 mg/kg injectable enrofloxacin for the treatment of Actinobacillus pleuropneumoniae infections in growing-fattening pigs in Europe

Grandemange, E.; Perrin, Pierre-Alexandre; Cvejic, Dejean; Haas, Miriam; Rowan, T.G.; Hellmann, Klaus

doi:10.1186/s40813-017-0057-2

Cited by 14 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acute clinical pleuropneumonia can be successfully treated by a single injection of fluoroquinolones in a dosage allowing concentration‐dependent bacterial killing, if App strains are susceptible (Grandemange et al., ). In an infection experiment, the high effectiveness of enrofloxacin against App compared to a tetracycline and procaine–penicillin was shown (Sjölund, Fossum, et al., ).…”

Section: Prevention Control and Treatmentmentioning

confidence: 99%

“…bial agents: ampicillin (sensitive <0.5, resistant >2.0), ceftiofur (sensi-tive <2, resistant >8.0), tulathromycin (sensitive <64), tilmicosin (sensitive <16, resistant >32), tildipirosin (sensitive <16), florfenicol (sensitive <2, resistant >8.0), tiamulin (sensitive <16, resistant >32), tetracycline (sensitive <0.5, resistant >2) (CLSI, 2015).Acute clinical pleuropneumonia can be successfully treated by a single injection of fluoroquinolones in a dosage allowing concentration-dependent bacterial killing, if App strains are susceptible(Grandemange et al, 2017). In an infection experiment, the high effectiveness of enrofloxacin against App compared to a tetracycline and procaine-penicillin was shown (Sj€ olund,Fossum, et al, 2011).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Update onActinobacillus pleuropneumoniae-knowledge, gaps and challenges

Sassu

Bossé

Tobias

et al. 2017

Transbound Emerg Dis

144

178

View full text Add to dashboard Cite

Summary Porcine pleuropneumonia, caused by the bacterial porcine respiratory tract pathogen Actinobacillus pleuropneumoniae, leads to high economic losses in affected swine herds in most countries of the world. Pigs affected by peracute and acute disease suffer from severe respiratory distress with high lethality. The agent was first described in 1957 and, since then, knowledge about the pathogen itself, and its interactions with the host, has increased continuously. This is, in part, due to the fact that experimental infections can be studied in the natural host. However, the fact that most commercial pigs are colonized by this pathogen has hampered the applicability of knowledge gained under experimental conditions. In addition, several factors are involved in development of disease, and these have often been studied individually. In a DISCONTOOLS initiative, members from science, industry and clinics exchanged their expertise and empirical observations and identified the major gaps in knowledge. This review sums up published results and expert opinions, within the fields of pathogenesis, epidemiology, transmission, immune response to infection, as well as the main means of prevention, detection and control. The gaps that still remain to be filled are highlighted, and present as well as future challenges in the control of this disease are addressed.

show abstract

Section: Prevention Control and Treatmentmentioning

confidence: 99%

mentioning

confidence: 99%

Update onActinobacillus pleuropneumoniae-knowledge, gaps and challenges

Sassu

Bossé

Tobias

et al. 2017

Transbound Emerg Dis

144

178

View full text Add to dashboard Cite

show abstract

“…However, it is reported that MR, as a single-dose of 10 mg/kg, could be effective in order to limit the risk of development of resistance, as multiple dosing of 2 mg/kg could achieve mutant prevention concentration (MPC) only for a short time after every dose (Vallé et al 2012 ). Based on this, we used MR as a single high dose as recommended for calves and pigs in previous studies (Grandemange et al 2012 , 2017 ).…”

Section: Discussionmentioning

confidence: 99%

Comparing clinical effects of marbofloxacin and gamithromycin in goat kids with pneumonia

Kaçar

Batmaz

Yılmaz

et al. 2018

J. S. Afr. Vet. Assoc.

View full text Add to dashboard Cite

The aim of this study was to compare the clinical efficacy of a single-dose of gamithromycin (GM) or marbofloxacin (MR) in kids with naturally occurring pneumonia. Thirty-six kids, aged 2–2.5 months, with body weight ranging from 12 kg to 18 kg were presented with clinical signs of pneumonia. The most prominent clinical findings were an increase in the respiratory rate, crackling lung sounds on auscultation, coughing, nasal discharge and an increased rectal temperature. Mannheimia haemolytica and Mycoplasma spp. colonies were isolated from microbiological examination of six transtracheal washes and lung tissues of one necropsied kid. The severity of pneumonia was evaluated by using cumulative clinical score (CCS). The CCS of the 36 kids used in the study were four and above. Kids were randomly divided into two equal groups; the GM group received a single subcutaneous dose of GM at a dosage of 6 mg/kg and the MR group received MR intramuscularly at a dosage of 8 mg/kg as a single-dose. No side effects related to the drugs were detected in either group. All 36 kids were clinically examined 3 weeks after the initiation of the treatment. Clinical signs in both groups were almost completely absent at the end of the study. A single administration of GM or MR was successfully used in the treatment of kids with pneumonia.

show abstract

“…The calculated PK/PD indices were AUC/ MIC90 for selected time intervals (0-24 h, 24-48 h, 48-72 h) divided by 24 h, as suggested by for long acting formulations, and Cmax/MIC90. These indices were calculated using MIC90 values for the most common pathogens in swine (Grandemange et al, 2017).…”

Section: Methodsmentioning

confidence: 99%

Pharmacokinetic / Pharmacodynamic Evaluation of Marbofloxacin for Common Pathogens in Swine Following Single Intramuscular Administration of Different Doses

Rambaldi¹,

Barbarossa²,

Morbidelli³

et al. 2018

PVJ

View full text Add to dashboard Cite

The aims of the present work were to study the pharmacokinetics of marbofloxacin 10% solution after single i.m. administration at doses of 6, 8, 10 mg/kg b.w. in swine of 20 weeks of age, to estimate the PK/PD indices using bibliographic MIC90 values and to assess the tolerability of the drug. Marbofloxacin Cmax increased in a dose dependent manner, however animals receiving the 10 mg/kg b.w. dose revealed slightly lower AUCi compared to those receiving 8 mg/kg b.w. This suggests a potential alteration of the elimination mechanisms, evidenced by Cltot values after administration of the three dosages. According to the results of the study, the three tested dosages are well tolerated and active for 2-3 days against the most common pathogens in swine. In particular, 8 mg/kg appeared to be the most suitable dose, since 6 mg/kg might be insufficient against the less susceptible pathogens and 10 mg/kg seemed not to provide any advantage.To Cite This Article: Rambaldi J, Barbarossa A, Morbidelli E and Zaghini A, 2018. Pharmacokinetic/ pharmacodynamic evaluation of marbofloxacin for common pathogens in swine following single intramuscular administration of different doses. Pak Vet J, 38(2): 222-224. http://dx.

show abstract

Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg/kg injectable dose of marbofloxacin compared with one or two doses of 7.5 mg/kg injectable enrofloxacin for the treatment of Actinobacillus pleuropneumoniae infections in growing-fattening pigs in Europe

Cited by 14 publications

References 20 publications

Update onActinobacillus pleuropneumoniae-knowledge, gaps and challenges

Update onActinobacillus pleuropneumoniae-knowledge, gaps and challenges

Comparing clinical effects of marbofloxacin and gamithromycin in goat kids with pneumonia

Pharmacokinetic / Pharmacodynamic Evaluation of Marbofloxacin for Common Pathogens in Swine Following Single Intramuscular Administration of Different Doses

Contact Info

Product

Resources

About